Axsome Therapeutics Inc AXS-12 Update Corporate Call Transcript
Good morning, ladies and gentlemen, and welcome to Axsome Therapeutics conference call. (Operator Instructions) This call is being webcast live on the webcast and presentation page of Axsome's website at axsome.com\http://axsome.com/. (Operator Instructions) Please note that today's conference is being recorded.
I would now like to turn the conference over to your host, Mark Jacobson, Chief Operating Officer at Axsome Therapeutics. Please go ahead.
Thank you, operator. Good morning, and thank you all for joining us on today's conference call. This call is to provide an update on our AXS-12 product candidate.
A short time ago, this morning, a press release crossed the wire announcing the expedited development plan for AXS-12 in the treatment of narcolepsy based on the outcome of our recent breakthrough therapy meeting with the U.S. Food and Drug Administration, or FDA. We will begin this call with prepared remarks by Dr. Herriot Tabuteau, Chief Executive Officer, and then open
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |